Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.
about
Optimizing antimicrobial therapy in critically ill patientsCorrelation between in vitro and in vivo activities of GM 237354, a new sordarin derivative, against Candida albicans in an in vitro pharmacokinetic-pharmacodynamic model and influence of protein bindingPopulation pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteersComparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo.Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics.Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.Combination therapy as a tool to prevent emergence of bacterial resistance.Altered pharmacokinetics of ceftazidime in critically ill patients.Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosingActivities of trovafloxacin and ampicillin-sulbactam alone or in combination versus three strains of vancomycin- intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.High-dose continuous oxacillin infusion results in achievement of pharmacokinetics targets in critically ill patients with deep sternal wound infections following cardiac surgery.What in vitro models of infection can and cannot do.Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infectionsAlteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic model.Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model.Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion.Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model.In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patientsHigh-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients.Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapyTherapeutic drug monitoring of antimicrobials.Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infectionsIn vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection.Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness.Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacyPharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.Pharmacokinetic/pharmacodynamic profiling of imipenem in patients admitted to an intensive care unit in India: A nonrandomized, cross-sectional, analytical, open-labeled study.Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.Continuous beta-lactam infusion in critically ill patients: the clinical evidenceVariability in plasma concentration of cefotaxime in critically ill patients in an Intensive Care Unit of India and its pharmacodynamic outcome: A nonrandomized, prospective, open-label, analytical studyImpact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa.Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation, and reason for admission.Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria.Novel concentration-killing curve method for estimation of bactericidal potency of antibiotics in an in vitro dynamic model.Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.
P2860
Q26999905-55F05272-AE12-43E6-B852-6ABFEB8B4ED8Q28353204-34ED91A3-81AD-4562-A6B0-B808A5078907Q33676387-1E13C961-AD7E-4756-88BD-64191AB99CBEQ33689995-86325EB3-EE67-4B55-952C-47ACDDE71303Q33692063-A812B968-E4D4-4A19-B080-F26C7F2340ACQ33722108-35FB8236-3458-48D9-A302-17DD8B0F4B7EQ33961767-6828C692-816E-4DF7-8C6D-5FB8160389E1Q33977268-13DD1329-F62F-4B21-8E9B-BFAC3292F587Q33977939-20221588-6C4F-46FD-A32F-208F4E125167Q33979347-9CCAD025-6CE7-4EBB-A169-44124B6620D8Q34057385-FB61F7C3-3DFD-4C43-8BB8-C5679E04629BQ34443398-3ADF074E-E28B-4137-804F-4029E4F280DAQ34510488-9B0438AE-20CE-410B-81D2-5180EBC713ADQ35117352-70673716-319F-46DF-9B22-CB4227326D6BQ35121441-9FA2C505-3FC9-4F69-AFDE-DD081C18E8D7Q35123123-EEE2C7EC-2C6C-41EA-AC4F-522D6401846CQ35123348-BD838E7D-0FF9-4D4F-AA70-D005FD345C3BQ35131156-A3958661-A2CD-49C3-ABBC-AE0F17FCA51BQ35134599-0263F7BF-761B-48D0-9424-DE6D64F6EB82Q35136449-07209FA2-2D29-4CC1-B109-D4EA1301600DQ35138316-5D2948CE-E61B-4ED3-8653-2187B6B38FDDQ35141040-D85FB85D-4B5F-4BDC-9DF6-6FAFED64B3A8Q35558292-18D5405D-8A9B-422C-B9C2-F2F1413EFB58Q35640430-32B1A377-363C-4FD1-879A-022A02388A77Q35759054-A7318C2B-A1EC-4D4A-9D2B-E79760F28C8CQ35941284-2E8DA9D5-A8BB-4048-9949-E3FB0705A2C0Q35944927-2B2096DB-C7CD-489A-B820-60BEB8798B4DQ36024915-7AA7BD2F-5747-4DD1-A3CA-71FF91D0DC76Q36053937-65288FF8-07A5-418E-A3F0-4E80B71E8064Q36094786-F8A5A710-403C-4128-95B9-FF53D345DB59Q36095041-EF9219B4-5DD7-4FDF-BBC5-F25484BB3F79Q36262753-54E3E70A-EECC-49EB-8CD9-237133B35C0BQ36287127-B0031327-E232-47F3-8C18-E66393E9A8A3Q36329228-E0057317-B6DC-4696-BD66-67C4F1C32C41Q36797704-60260B3E-41AA-45FE-9794-7038702CD96DQ37335725-E04A50DD-9821-4AB0-A577-3C5401D46B52Q37392874-10CD2BA8-9DDD-45EC-B4E0-4BFBAC607307Q37543906-CD04ABF8-4DE1-44BE-AF6E-5FE75B3B2951Q37568944-0792A082-823E-44CD-9F7B-22232A31B353Q37642084-9BD75517-946C-4233-B6FE-0E98F65A4C24
P2860
Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Killing of Pseudomonas aerugin ...... n vitro pharmacokinetic model.
@ast
Killing of Pseudomonas aerugin ...... n vitro pharmacokinetic model.
@en
type
label
Killing of Pseudomonas aerugin ...... n vitro pharmacokinetic model.
@ast
Killing of Pseudomonas aerugin ...... n vitro pharmacokinetic model.
@en
prefLabel
Killing of Pseudomonas aerugin ...... n vitro pharmacokinetic model.
@ast
Killing of Pseudomonas aerugin ...... n vitro pharmacokinetic model.
@en
P2860
P356
P1476
Killing of Pseudomonas aerugin ...... n vitro pharmacokinetic model.
@en
P2093
den Hollander JG
P2860
P304
P356
10.1128/AAC.38.5.931
P407
P577
1994-05-01T00:00:00Z